Literature DB >> 6286

Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels.

F J Kogan, W K Nichols, J W Gibb.   

Abstract

In previous reports, methamphetamine was shown to depress tyrosine hydroxylase (TH) activity in the rat corpus striatum. To evaluate further the mechanism of this decrease in TH activity, enzyme activity was measured in the rat corpus striatum and substantia nigra after repetitive and single-dose methamphetamine administration. Following repeated doses of methamphetamine, nigral TH activity decreased and reached 45% of controls at 12 hr and returned to normal at 60 hr. Striatal TH activity decreased to 40% of control at 36 hr and returned toward normal at 60 hr. When methamphetamine was administered every 6 hr for 30 hr and then discontinued, nigral TH activity returned toward control levels 4 days prior to recovery of striatal TH activity. Methamphetamine initially increased striatal dopamine levels at 6 hr (170% of control). Dopamine levels then decreased in parallel with striatal TH activity but failed to increase as the enzyme recovered. Concurrent administration of chlorpromazine with methamphetamine prevented the methamphetamine-induced decrease in nigral and striatal TH activity and striatal dopamine levels. The results indicate that the methamphetamine-induced depression of striatal and nigral TH activity may be related to increased stimulation of dopamine receptors in the striatum.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 6286     DOI: 10.1016/0014-2999(76)90090-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  57 in total

1.  Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Authors:  Pei-Wen Chu; Gregory C Hadlock; Paula Vieira-Brock; Kristen Stout; Glen R Hanson; Annette E Fleckenstein
Journal:  J Neurochem       Date:  2010-08-25       Impact factor: 5.372

2.  Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia.

Authors:  Michelle G Baladi; Amy H Newman; Shannon M Nielsen; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2014-03-28       Impact factor: 4.432

3.  A role for D1 dopamine receptors in striatal methamphetamine-induced neurotoxicity.

Authors:  Danielle M Friend; Kristen A Keefe
Journal:  Neurosci Lett       Date:  2013-08-28       Impact factor: 3.046

Review 4.  Methamphetamine-induced neuronal apoptosis involves the activation of multiple death pathways. Review.

Authors:  Jean Lud Cadet; Subramaniam Jayanthi; Xiaolin Deng
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

Review 5.  HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse.

Authors:  Kurt F Hauser; Nazira El-Hage; Anne Stiene-Martin; William F Maragos; Avindra Nath; Yuri Persidsky; David J Volsky; Pamela E Knapp
Journal:  J Neurochem       Date:  2006-12-01       Impact factor: 5.372

6.  The Basal Ganglia as a Substrate for the Multiple Actions of Amphetamines.

Authors:  Reka Natarajan; Bryan K Yamamoto
Journal:  Basal Ganglia       Date:  2011-07-01

Review 7.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Methamphetamine alters reference gene expression in nigra and striatum of adult rat brain.

Authors:  Yi He; Seongjin Yu; Eunkyung Bae; Hui Shen; Yun Wang
Journal:  Neurotoxicology       Date:  2013-09-14       Impact factor: 4.294

9.  Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats.

Authors:  Kamisha L Johnson-Davis; Glen R Hanson; Kristen A Keefe
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 10.  Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.

Authors:  Annette E Fleckenstein; Trent J Volz; Glen R Hanson
Journal:  Neuropharmacology       Date:  2008-07-10       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.